Industry News
Excerpt from the Press Release: LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the peer-reviewed publication of preclinical results of its COVID-19 vaccine candidate, MRT5500, in the journal npj Vaccines. Preclinical evaluation of MRT5500 demonstrated a favorable immune response profile against SARS-CoV-2 and…
Read More
Excerpt from the Press Release: FRAMINGHAM, Mass., April 19, 2021 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today provided the following corporate update, in line with its commitment to maintain continuing dialogue with investors and other stakeholders on the progress and…
Read More
Excerpt from the Article: Leftover drops in vials of Moderna’s COVID-19 vaccine allowed a group of researchers from Stanford University to determine the sequence of the mRNA for SARS-CoV-2’s spike protein that is used in the immunization, Motherboard reported March 29. The sequence has been posted on the open-access website GitHub. “Sharing of sequence information…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today highlighted the publication of antibody persistence data out to 6 months following the second dose of the Moderna COVID-19 Vaccine in The New England Journal of Medicine. “We are pleased that this new…
Read More
Excerpt from the Press Release: INDIANAPOLIS, April 8, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which…
Read More
Excerpt from the Press Release: DUBLIN, Ireland and TREVOSE, Pa., April 07, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that results from a subanalysis of patients with diabetes mellitus from the…
Read More
Our April virtual networking meeting is next week! Join Heather and Christopher, and their guest, John Amrhein from McDougall Scientific on April 21st, 8 pm EST for this exciting discussion on the crucial need to involve statisticians early in the clinical trial design process! To register for your complimentary ticket, click the image or button…
Read More
Excerpt from the Press Release: SAN FRANCISCO, April 8, 2021 /PRNewswire/ — Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Human Genome Research Institute (NHGRI) that connects genetic data and electronic medical record (EMR) systems to advance the use of genetics…
Read More
Excerpt from the Press Release: SAN DIEGO, March 30, 2021 /PRNewswire/ — HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab),…
Read More Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Mar. 31, 2021– Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for advanced renal cell carcinoma (RCC). This approval allows for the marketing of CABOMETYX in combination with…
Read More